{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:32:53Z","timestamp":1786361573682,"version":"build-2736575974"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005711","name":"Universit\u00e4t Hamburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bevacizumab is widely used as an anti-angiogenic maintenance therapy in ovarian cancer; however, there are currently no validated clinical criteria to guide patient selection for its use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To satisfy the urgent need for bevacizumab response biomarkers, we created a novel RNA-seq dataset (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009244) and applied unsupervised and supervised machine learning to identify expression signatures associated with benefit from adding bevacizumab to standard treatment and validated our findings using a previously published microarray dataset (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009377). Additionally, we validated the existence of the discovered signatures using RNA-seq data from the TCGA-OV cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009426) and performed public expression data mining to provide a biological interpretation of the prioritized signature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among expression signatures reproducibly detected in independent datasets, one was prioritized as a potential predictive biomarker for bevacizumab benefit. Further stratified analysis revealed that over-expression of this signature was associated with improved overall survival in patients who received bevacizumab in addition to standard chemotherapy in both novel (HR\u2009=\u20090.41, 95% CI: (0.23\u20130.74), adj.\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009=\u20090.008) and previously published cohorts (HR\u2009=\u20090.51, 95% CI: (0.34\u20130.75), adj.\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009=\u20090.003), while no significant survival benefit from bevacizumab was observed in patients negative for this signature. We hypothesize that this signature may be associated with stemness-like features, possibly driven by\n                      <jats:italic>CTCFL<\/jats:italic>\n                      . In addition, we identified several other signatures reproducible in independent datasets and not related to known molecular subtypes of ovarian cancer, which may also represent biomarker candidates and require further validation in additional RNA-seq data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified a previously undescribed expression signature with potential predictive value for bevacizumab benefit, and revealed transcriptional heterogeneity of ovarian cancer that extends beyond current molecular classifications. Given the high heterogeneity of ovarian cancer and that the novel signature only partially explains variation in survival outcomes under bevacizumab treatment, larger RNA-seq datasets are required to further improve predictive models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-026-01727-6","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:48:50Z","timestamp":1785941330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transcriptome signatures for the identification of bevacizumab responders in ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9424-8052","authenticated-orcid":false,"given":"Olga","family":"Zolotareva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Legler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Tsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Sergushichev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Sukhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Baumbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Eylmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyue","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Oliveira-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"1727_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21:389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"key":"1727_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","volume":"35","author":"JA Ledermann","year":"2024","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35:248\u201366.","journal-title":"Ann Oncol"},{"key":"1727_CR3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med"},{"key":"1727_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1758834012467661","volume":"5","author":"A Garcia","year":"2013","unstructured":"Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol. 2013;5:133\u201341.","journal-title":"Ther Adv Med Oncol"},{"key":"1727_CR5","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"1727_CR6","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1158\/1078-0432.CCR-13-0489","volume":"19","author":"F Collinson","year":"2013","unstructured":"Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res. 2013;19:5227\u201339.","journal-title":"Clin Cancer Res"},{"key":"1727_CR7","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-13-3248","volume":"20","author":"A Backen","year":"2014","unstructured":"Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res. 2014;20:4549\u201358.","journal-title":"Clin Cancer Res"},{"key":"1727_CR8","doi-asserted-by":"publisher","first-page":"e0269680","DOI":"10.1371\/journal.pone.0269680","volume":"17","author":"Y Ding","year":"2022","unstructured":"Ding Y, Oliveira-Ferrer L, Vettorazzi E, Legler K, Milde-Langosch K, Woelber L, et al. VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients. PLoS One. 2022;17:e0269680.","journal-title":"PLoS One"},{"key":"1727_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/IGC.0000000000001027","volume":"27","author":"H Komatsu","year":"2017","unstructured":"Komatsu H, Oishi T, Itamochi H, Shimada M, Sato S, Chikumi J, et al. Serum vascular endothelial growth factor-A as a prognostic biomarker for epithelial ovarian cancer. Int J Gynecol Cancer. 2017;27:1325\u201332.","journal-title":"Int J Gynecol Cancer"},{"key":"1727_CR10","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/IGC.0000000000000798","volume":"26","author":"MK Boisen","year":"2016","unstructured":"Boisen MK, Madsen CV, Dehlendorff C, Jakobsen A, Johansen JS, Steffensen KD. The prognostic value of plasma YKL-40 in patients with chemotherapy-resistant ovarian cancer treated with bevacizumab. Int J Gynecol Cancer. 2016;26:1390\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"1727_CR11","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37:2317\u201328.","journal-title":"J Clin Oncol"},{"key":"1727_CR12","doi-asserted-by":"publisher","unstructured":"Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, et al. Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst. 2017;109. https:\/\/doi.org\/10.1093\/jnci\/djx066.","DOI":"10.1093\/jnci\/djx066"},{"key":"1727_CR13","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1158\/1078-0432.CCR-22-1326","volume":"28","author":"P Wimberger","year":"2022","unstructured":"Wimberger P, Gerber MJ, Pfisterer J, Erdmann K, F\u00fcssel S, Link T, et al. Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an antiangiogenic VEGF-A splice variant. Clin Cancer Res. 2022;28:4660\u20138.","journal-title":"Clin Cancer Res"},{"key":"1727_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12916-022-02270-y","volume":"20","author":"RD Morgan","year":"2022","unstructured":"Morgan RD, Ferreras C, Peset I, Avizienyte E, Renehan AG, Edmondson RJ, et al. C-MET\/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. BMC Med. 2022;20:59.","journal-title":"BMC Med"},{"key":"1727_CR15","doi-asserted-by":"publisher","first-page":"15957","DOI":"10.1007\/s00432-023-05354-1","volume":"149","author":"A Volk","year":"2023","unstructured":"Volk A, Legler K, Hamester F, Kuerti S, Eylmann K, Rossberg M, et al. Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer. J Cancer Res Clin Oncol. 2023;149:15957\u201367.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1727_CR16","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-16-2196","volume":"23","author":"S Kommoss","year":"2017","unstructured":"Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res. 2017;23:3794\u2013801.","journal-title":"Clin Cancer Res"},{"key":"1727_CR17","doi-asserted-by":"publisher","unstructured":"Califano D, Gallo D, Rampioni Vinciguerra GL, De Cecio R, Arenare L, Signoriello S, et al. Evaluation of angiogenesis-related genes as prognostic biomarkers of bevacizumab treated ovarian cancer patients: results from the phase IV MITO16A\/ManGO OV-2 translational study. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13205152.","DOI":"10.3390\/cancers13205152"},{"key":"1727_CR18","doi-asserted-by":"publisher","first-page":"43218","DOI":"10.18632\/oncotarget.17978","volume":"8","author":"S Kuerti","year":"2017","unstructured":"Kuerti S, Oliveira-Ferrer L, Milde-Langosch K, Schmalfeldt B, Legler K, Woelber L, et al. VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients. Oncotarget. 2017;8:43218\u201327.","journal-title":"Oncotarget"},{"key":"1727_CR19","doi-asserted-by":"publisher","first-page":"1250258","DOI":"10.3389\/fimmu.2023.1250258","volume":"14","author":"F Brauneck","year":"2023","unstructured":"Brauneck F, Oliveira-Ferrer L, Muschhammer J, Sturmheit T, Ackermann C, Haag F, et al. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells. Front Immunol. 2023;14:1250258.","journal-title":"Front Immunol"},{"key":"1727_CR20","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884\u201390.","journal-title":"Bioinformatics"},{"key":"1727_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"1727_CR22","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.","journal-title":"Genome Biol"},{"key":"1727_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1727_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"1727_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138.","journal-title":"Nat Biotechnol"},{"key":"1727_CR26","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-18-0784","volume":"24","author":"GM Chen","year":"2018","unstructured":"Chen GM, Kannan L, Geistlinger L, Kofia V, Safikhani Z, Gendoo DMA, et al. Consensus on molecular subtypes of high-grade serous ovarian carcinoma. Clin Cancer Res. 2018;24:5037\u201347.","journal-title":"Clin Cancer Res"},{"key":"1727_CR27","doi-asserted-by":"publisher","unstructured":"Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014;106. https:\/\/doi.org\/10.1093\/jnci\/dju249.","DOI":"10.1093\/jnci\/dju249"},{"key":"1727_CR28","first-page":"517","volume":"123","author":"RGW Verhaak","year":"2013","unstructured":"Verhaak RGW, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123:517\u201325.","journal-title":"J Clin Invest"},{"key":"1727_CR29","doi-asserted-by":"publisher","first-page":"e18064","DOI":"10.1371\/journal.pone.0018064","volume":"6","author":"\u00c5 Helland","year":"2011","unstructured":"Helland \u00c5, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One. 2011;6:e18064.","journal-title":"PLoS One"},{"key":"1727_CR30","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1158\/1078-0432.CCR-20-0103","volume":"26","author":"A Talhouk","year":"2020","unstructured":"Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, et al. Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clin Cancer Res. 2020;26:5411\u201323.","journal-title":"Clin Cancer Res"},{"key":"1727_CR31","unstructured":"Hartung M, Maier A, Burankova Y, Delgado-Chaves F, Isaeva OI, Savchik A, et al. UnPaSt: unsupervised patient stratification by biclustering of omics data. arXiv; 2025. Available from: https:\/\/arxiv.org\/abs\/2408.00200v2."},{"key":"1727_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1214\/08-AOAS169","volume":"2","author":"H Ishwaran","year":"2008","unstructured":"Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Stat. 2008;2:841\u201360.","journal-title":"Ann Appl Stat"},{"key":"1727_CR33","first-page":"1","volume":"21","author":"S P\u00f6lsterl","year":"2020","unstructured":"P\u00f6lsterl S. scikit-survival: a library for time-to-event analysis built on top of scikit-learn. J Mach Learn Res. 2020;21:1\u20136.","journal-title":"J Mach Learn Res"},{"key":"1727_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45:5\u201332.","journal-title":"Mach Learn"},{"key":"1727_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.21105\/joss.01317","volume":"4","author":"C Davidson-Pilon","year":"2019","unstructured":"Davidson-Pilon C. lifelines: survival analysis in Python. J Open Source Softw. 2019;4:1317.","journal-title":"J Open Source Softw"},{"key":"1727_CR36","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"1727_CR37","doi-asserted-by":"publisher","unstructured":"Fang Z, Liu X, Peltz G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics. 2023;39. https:\/\/doi.org\/10.1093\/bioinformatics\/btac757.","DOI":"10.1093\/bioinformatics\/btac757"},{"key":"1727_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25\u20139.","journal-title":"Nat Genet"},{"key":"1727_CR39","doi-asserted-by":"publisher","unstructured":"Gene Ontology Consortium, Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, et al. The gene ontology knowledgebase in 2023. Genetics. 2023;224. https:\/\/doi.org\/10.1093\/genetics\/iyad031.","DOI":"10.1093\/genetics\/iyad031"},{"key":"1727_CR40","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52:D672\u20138.","journal-title":"Nucleic Acids Res"},{"key":"1727_CR41","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gky1032","volume":"47","author":"LM Schriml","year":"2018","unstructured":"Schriml LM, Mitraka E, Munro J, Tauber B, Schor M, Nickle L, et al. Human disease ontology 2018 update: classification, content and workflow expansion. Nucleic Acids Res. 2018;47:D955\u201362.","journal-title":"Nucleic Acids Res"},{"key":"1727_CR42","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587\u201392.","journal-title":"Nucleic Acids Res"},{"key":"1727_CR43","doi-asserted-by":"publisher","first-page":"D679","DOI":"10.1093\/nar\/gkad960","volume":"52","author":"A Agrawal","year":"2024","unstructured":"Agrawal A, Balc\u0131 H, Hanspers K, Coort SL, Martens M, Slenter DN, et al. Wikipathways 2024: next generation pathway database. Nucleic Acids Res. 2024;52:D679\u201389.","journal-title":"Nucleic Acids Res"},{"key":"1727_CR44","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"GTEx Consortium","year":"2020","unstructured":"GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318\u201330.","journal-title":"Science"},{"key":"1727_CR45","doi-asserted-by":"publisher","unstructured":"Cao J, O\u2019Day DR, Pliner HA, Kingsley PD, Deng M, Daza RM, et al. A human cell atlas of fetal gene expression. Science. 2020;370. https:\/\/doi.org\/10.1126\/science.aba7721.","DOI":"10.1126\/science.aba7721"},{"key":"1727_CR46","doi-asserted-by":"publisher","first-page":"D870","DOI":"10.1093\/nar\/gkac947","volume":"51","author":"C Hu","year":"2023","unstructured":"Hu C, Li T, Xu Y, Zhang X, Li F, Bai J, et al. CellMarker 2.0: an updated database of manually curated cell markers in human\/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 2023;51:D870\u20136.","journal-title":"Nucleic Acids Res"},{"key":"1727_CR47","doi-asserted-by":"publisher","first-page":"eabl4896","DOI":"10.1126\/science.abl4896","volume":"376","author":"RC Jones","year":"2022","unstructured":"Tabula Sapiens Consortium*, Jones RC, Karkanias J, Krasnow MA, Pisco AO, Quake SR, et al. The Tabula Sapiens: a multiple-organ, single-cell transcriptomic atlas of humans. Science. 2022;376:eabl4896.","journal-title":"Science"},{"key":"1727_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"key":"1727_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"1727_CR50","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41586-024-07585-9","volume":"631","author":"P Mehrotra","year":"2024","unstructured":"Mehrotra P, Maschalidi S, Boeckaerts L, Mauer\u00f6der C, Tixeira R, Pinney J, et al. Oxylipins and metabolites from pyroptotic cells act as promoters of tissue repair. Nature. 2024;631:207\u201315.","journal-title":"Nature"},{"key":"1727_CR51","doi-asserted-by":"publisher","first-page":"W187","DOI":"10.1093\/nar\/gkaf372","volume":"53","author":"V Sukhov","year":"2025","unstructured":"Sukhov V, Nugmanova A, Vorontsov Y, Mehrotra P, Kleverov M, Ravichandran K, et al. CORESH: a gene signature-based search engine for public gene expression datasets. Nucleic Acids Res. 2025;53:W187\u201392.","journal-title":"Nucleic Acids Res"},{"key":"1727_CR52","doi-asserted-by":"publisher","first-page":"D138","DOI":"10.1093\/nar\/gkad965","volume":"52","author":"E Clough","year":"2024","unstructured":"Clough E, Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, et al. NCBI GEO: archive for gene expression and epigenomics data sets: 23-year update. Nucleic Acids Res. 2024;52:D138\u201344.","journal-title":"Nucleic Acids Res"},{"key":"1727_CR53","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41467-018-03751-6","volume":"9","author":"A Lachmann","year":"2018","unstructured":"Lachmann A, Torre D, Keenan AB, Jagodnik KM, Lee HJ, Wang L, et al. Massive mining of publicly available RNA-seq data from human and mouse. Nat Commun. 2018;9:1366.","journal-title":"Nat Commun"},{"key":"1727_CR54","doi-asserted-by":"publisher","unstructured":"Ziemann M, Kaspi A, El-Osta A. Digital expression explorer 2: a repository of uniformly processed RNA sequencing data. Gigascience. 2019;8. https:\/\/doi.org\/10.1093\/gigascience\/giz022.","DOI":"10.1093\/gigascience\/giz022"},{"key":"1727_CR55","doi-asserted-by":"crossref","unstructured":"Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. bioRxiv. bioRxiv; 2016. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/060012.","DOI":"10.1101\/060012"},{"key":"1727_CR56","doi-asserted-by":"publisher","first-page":"e30269","DOI":"10.1371\/journal.pone.0030269","volume":"7","author":"S Bentink","year":"2012","unstructured":"Bentink S, Haibe-Kains B, Risch T, Fan J-B, Hirsch MS, Holton K, et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One. 2012;7:e30269.","journal-title":"PLoS One"},{"key":"1727_CR57","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fonc.2020.00221","volume":"10","author":"Y Haibe","year":"2020","unstructured":"Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, et al. Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol. 2020;10:221.","journal-title":"Front Oncol"},{"key":"1727_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ygyno.2014.01.031","volume":"133","author":"KN Slaughter","year":"2014","unstructured":"Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, et al. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014;133:11\u20135.","journal-title":"Gynecol Oncol"},{"key":"1727_CR59","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3892\/ol.2016.4648","volume":"12","author":"Y Wang","year":"2016","unstructured":"Wang Y, Thai T, Moore K, Ding K, McMeekin S, Liu H, et al. Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients. Oncol Lett. 2016;12:680\u20136.","journal-title":"Oncol Lett"},{"key":"1727_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/gut.2009.188946","volume":"59","author":"B Guiu","year":"2010","unstructured":"Guiu B, Petit JM, Bonnetain F, Ladoire S, Guiu S, Cercueil JP, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut. 2010;59:341\u20137.","journal-title":"Gut"},{"key":"1727_CR61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1634\/theoncologist.2010-0227","volume":"16","author":"S Ladoire","year":"2011","unstructured":"Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist. 2011;16:71\u201381.","journal-title":"Oncologist"},{"key":"1727_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ygyno.2019.07.020","volume":"155","author":"KNS Wade","year":"2019","unstructured":"Wade KNS, Brady MF, Thai T, Wang Y, Zheng B, Salani R, et al. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: an NRG Oncology\/Gynecologic Oncology Group ancillary data analysis of GOG 218. Gynecol Oncol. 2019;155:69\u201374.","journal-title":"Gynecol Oncol"},{"key":"1727_CR63","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/sj.ijo.0802987","volume":"29","author":"JV Silha","year":"2005","unstructured":"Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005;29:1308\u201314.","journal-title":"Int J Obes (Lond)"},{"key":"1727_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fonc.2014.00069","volume":"4","author":"C Stockmann","year":"2014","unstructured":"Stockmann C, Schadendorf D, Klose R, Helfrich I. The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol. 2014;4:69.","journal-title":"Front Oncol"},{"key":"1727_CR65","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1083\/jcb.138.3.707","volume":"138","author":"DW Dawson","year":"1997","unstructured":"Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997;138:707\u201317.","journal-title":"J Cell Biol"},{"key":"1727_CR66","doi-asserted-by":"publisher","first-page":"re3","DOI":"10.1126\/scisignal.272re3","volume":"2","author":"RL Silverstein","year":"2009","unstructured":"Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2:re3.","journal-title":"Sci Signal"},{"key":"1727_CR67","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1161\/01.ATV.0000098644.03153.6F","volume":"23","author":"D Liu","year":"2003","unstructured":"Liu D, Jia H, Holmes DIR, Stannard A, Zachary I. Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1. Arterioscler Thromb Vasc Biol. 2003;23:2002\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1727_CR68","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.atherosclerosis.2005.04.008","volume":"184","author":"J Rius","year":"2006","unstructured":"Rius J, Mart\u00ednez-Gonz\u00e1lez J, Crespo J, Badimon L. NOR-1 is involved in VEGF-induced endothelial cell growth. Atherosclerosis. 2006;184:276\u201382.","journal-title":"Atherosclerosis"},{"key":"1727_CR69","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1084\/jem.20051523","volume":"203","author":"H Zeng","year":"2006","unstructured":"Zeng H, Qin L, Zhao D, Tan X, Manseau EJ, Van Hoang M, et al. Orphan nuclear receptor TR3\/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. J Exp Med. 2006;203:719\u201329.","journal-title":"J Exp Med"},{"key":"1727_CR70","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-16-3153","volume":"23","author":"C Carbone","year":"2017","unstructured":"Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, et al. Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients. Clin Cancer Res. 2017;23:4312\u201322.","journal-title":"Clin Cancer Res"},{"key":"1727_CR71","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1073\/pnas.042416199","volume":"99","author":"A Dobolyi","year":"2002","unstructured":"Dobolyi A, Ueda H, Uchida H, Palkovits M, Usdin TB. Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci U S A. 2002;99:1651\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1727_CR72","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00429-011-0357-2","volume":"217","author":"T Varga","year":"2012","unstructured":"Varga T, Mogyor\u00f3di B, Bag\u00f3 AG, Cserven\u00e1k M, Domokos D, Renner E, et al. Paralemniscal TIP39 is induced in rat dams and may participate in maternal functions. Brain Struct Funct. 2012;217:323\u201335.","journal-title":"Brain Struct Funct"},{"key":"1727_CR73","doi-asserted-by":"publisher","unstructured":"Wang X, Cheng X, Zhao L, Wang Y, Ye C, Zou X, et al. Molecular insights into differentiated ligand recognition of the human parathyroid hormone receptor 2. Proc Natl Acad Sci U S A. 2021;118. https:\/\/doi.org\/10.1073\/pnas.2101279118.","DOI":"10.1073\/pnas.2101279118"},{"key":"1727_CR74","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jid.2017.05.001","volume":"137","author":"TA Wilgus","year":"2017","unstructured":"Wilgus TA. New mechanisms of ECM production during wound healing: a role for parathyroid hormone 2 receptor signaling. J Invest Dermatol. 2017;137:1617\u20139.","journal-title":"J Invest Dermatol"},{"key":"1727_CR75","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1006\/bbrc.1994.1107","volume":"198","author":"E Rian","year":"1994","unstructured":"Rian E, Jemtland R, Olstad OK, Endresen MJ, Grasser WA, Thiede MA, et al. Parathyroid hormone-related protein is produced by cultured endothelial cells: a possible role in angiogenesis. Biochem Biophys Res Commun. 1994;198:740\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1727_CR76","doi-asserted-by":"publisher","first-page":"e87288","DOI":"10.1371\/journal.pone.0087288","volume":"9","author":"RAGMF Aversi-Ferreira","year":"2014","unstructured":"Aversi-Ferreira RAGMF, Souto Maior R, Aziz A, Ziermann JM, Nishijo H, Tomaz C, et al. Anatomical analysis of thumb opponency movement in the capuchin monkey (Sapajus sp). PLoS One. 2014;9:e87288.","journal-title":"PLoS One"},{"key":"1727_CR77","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12935-022-02566-2","volume":"22","author":"W Xiaowei","year":"2022","unstructured":"Xiaowei W, Tong L, Yanjun Q, Lili F. PTH2R is related to cell proliferation and migration in ovarian cancer: a multi-omics analysis of bioinformatics and experiments. Cancer Cell Int. 2022;22:148.","journal-title":"Cancer Cell Int"},{"key":"1727_CR78","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.canlet.2014.09.025","volume":"356","author":"S Brenner","year":"2015","unstructured":"Brenner S, Klameth L, Riha J, Sch\u00f6lm M, Hamilton G, Bajna E, et al. Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy. Cancer Lett. 2015;356:517\u201324.","journal-title":"Cancer Lett"},{"key":"1727_CR79","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.7150\/jca.65071","volume":"13","author":"Z Fang","year":"2022","unstructured":"Fang Z, Ruan B, Zhong M, Xiong J, Jiang Y, Song Z. Silencing LINC00491 inhibits pancreatic cancer progression through MiR-188-5p-induced Inhibition of ZFP91. J Cancer. 2022;13:1808\u201319.","journal-title":"J Cancer"},{"key":"1727_CR80","doi-asserted-by":"publisher","unstructured":"Wan H, Lin T, Shan M, Lu J, Guo Z. LINC00491 facilitates tumor progression of lung adenocarcinoma via Wnt\/\u03b2-catenin-signaling pathway by regulating MTSS1 ubiquitination. Cells. 2022;11. https:\/\/doi.org\/10.3390\/cells11233737.","DOI":"10.3390\/cells11233737"},{"key":"1727_CR81","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12935-018-0650-8","volume":"18","author":"S Soltanian","year":"2018","unstructured":"Soltanian S, Dehghani H. BORIS: a key regulator of cancer stemness. Cancer Cell Int. 2018;18:154.","journal-title":"Cancer Cell Int"},{"key":"1727_CR82","doi-asserted-by":"publisher","first-page":"e109921","DOI":"10.1371\/journal.pone.0109921","volume":"9","author":"L Alberti","year":"2014","unstructured":"Alberti L, Renaud S, Losi L, Leyvraz S, Benhattar J. High expression of hTERT and stemness genes in BORIS\/CTCFL positive cells isolated from embryonic cancer cells. PLoS One. 2014;9:e109921.","journal-title":"PLoS One"},{"key":"1727_CR83","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1158\/1541-7786.MCR-19-0310","volume":"17","author":"JC Hillman","year":"2019","unstructured":"Hillman JC, Pugacheva EM, Barger CJ, Sribenja S, Rosario S, Albahrani M, et al. Expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through. Mol Cancer Res. 2019;17:2051\u201362.","journal-title":"Mol Cancer Res"},{"key":"1727_CR84","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13059-015-0736-8","volume":"16","author":"EM Pugacheva","year":"2015","unstructured":"Pugacheva EM, Rivero-Hinojosa S, Espinoza CA, M\u00e9ndez-Catal\u00e1 CF, Kang S, Suzuki T, et al. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions. Genome Biol. 2015;16:161.","journal-title":"Genome Biol"},{"key":"1727_CR85","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13059-024-03175-0","volume":"25","author":"EM Pugacheva","year":"2024","unstructured":"Pugacheva EM, Bhatt DN, Rivero-Hinojosa S, Tajmul M, Fedida L, Price E, et al. BORIS\/CTCFL epigenetically reprograms clustered CTCF binding sites into alternative transcriptional start sites. Genome Biol. 2024;25:40.","journal-title":"Genome Biol"},{"key":"1727_CR86","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.gde.2020.02.021","volume":"61","author":"RE Debaugny","year":"2020","unstructured":"Debaugny RE, Skok JA. CTCF and CTCFL in cancer. Curr Opin Genet Dev. 2020;61:44\u201352.","journal-title":"Curr Opin Genet Dev"},{"key":"1727_CR87","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41540-022-00214-z","volume":"8","author":"M Salgado-Albarr\u00e1n","year":"2022","unstructured":"Salgado-Albarr\u00e1n M, Sp\u00e4th J, Gonz\u00e1lez-Barrios R, Baumbach J, Soto-Reyes E. CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy. NPJ Syst Biol Appl. 2022;8:5.","journal-title":"NPJ Syst Biol Appl"},{"key":"1727_CR88","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-019-1472-0","volume":"572","author":"DN Debruyne","year":"2019","unstructured":"Debruyne DN, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, et al. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature. 2019;572:676\u201380.","journal-title":"Nature"},{"key":"1727_CR89","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198\u2013208.","journal-title":"Clin Cancer Res"},{"key":"1727_CR90","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.joca.2020.03.015","volume":"28","author":"J Heilig","year":"2020","unstructured":"Heilig J, Dietmar HF, Brachvogel B, Paulsson M, Zaucke F, Niehoff A. Collagen IX deficiency leads to premature vascularization and ossification of murine femoral heads through an imbalance of pro- and antiangiogenic factors. Osteoarthritis Cartil. 2020;28:988\u201399.","journal-title":"Osteoarthritis Cartil"},{"key":"1727_CR91","doi-asserted-by":"publisher","first-page":"e3667","DOI":"10.1002\/jgm.3667","volume":"26","author":"J Chen","year":"2024","unstructured":"Chen J, Lu J, Chen Z, Liu Z, Sun Y, He S, et al. SPINK5 inhibits esophageal squamous cell carcinoma metastasis via immune activity. J Gene Med. 2024;26:e3667.","journal-title":"J Gene Med"},{"key":"1727_CR92","doi-asserted-by":"publisher","first-page":"1127448","DOI":"10.3389\/fonc.2023.1127448","volume":"13","author":"P Chen","year":"2023","unstructured":"Chen P, Bi F, Tan W, Jian L, Yu X. A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer. Front Oncol. 2023;13:1127448.","journal-title":"Front Oncol"},{"key":"1727_CR93","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1073\/pnas.151151198","volume":"98","author":"M Song","year":"2001","unstructured":"Song M, Ramaswamy S, Ramachandran S, Flowers LC, Horowitz IR, Rock JA, et al. Angiogenic role for glycodelin in tumorigenesis. Proc Natl Acad Sci U S A. 2001;98:9265\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1727_CR94","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/1756-0500-5-551","volume":"5","author":"C Scholz","year":"2012","unstructured":"Scholz C, Heublein S, Lenhard M, Friese K, Mayr D, Jeschke U. Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. BMC Res Notes. 2012;5:551.","journal-title":"BMC Res Notes"},{"key":"1727_CR95","doi-asserted-by":"publisher","first-page":"e0132977","DOI":"10.1371\/journal.pone.0132977","volume":"10","author":"L Alberti","year":"2015","unstructured":"Alberti L, Losi L, Leyvraz S, Benhattar J. Different effects of BORIS\/CTCFL on stemness gene expression, sphere formation and cell survival in epithelial cancer stem cells. PLoS One. 2015;10:e0132977.","journal-title":"PLoS One"},{"key":"1727_CR96","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1038\/ncomms2992","volume":"4","author":"U Ben-David","year":"2013","unstructured":"Ben-David U, Nudel N, Benvenisty N. Immunologic and chemical targeting of the tight-junction protein claudin-6 eliminates tumorigenic human pluripotent stem cells. Nat Commun. 2013;4:1992.","journal-title":"Nat Commun"},{"key":"1727_CR97","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/j.1365-2559.2012.04314.x","volume":"61","author":"T Ushiku","year":"2012","unstructured":"Ushiku T, Shinozaki-Ushiku A, Maeda D, Morita S, Fukayama M. Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. Histopathology. 2012;61:1043\u201356.","journal-title":"Histopathology"},{"key":"1727_CR98","doi-asserted-by":"publisher","unstructured":"Lisica \u0160iki\u0107 N, Petri\u0107 Mi\u0161e B, Tomi\u0107 S, Spagnol G, Matak L, Jureti\u0107 A, et al. MAGE-A10 protein expression in advanced high grade serous ovarian cancer is associated with resistance to first-line platinum-based chemotherapy. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15194697.","DOI":"10.3390\/cancers15194697"},{"key":"1727_CR99","doi-asserted-by":"publisher","first-page":"108276","DOI":"10.1016\/j.celrep.2020.108276","volume":"33","author":"Y Hu","year":"2020","unstructured":"Hu Y, Pan J, Shah P, Ao M, Thomas SN, Liu Y, et al. Integrated proteomic and glycoproteomic characterization of human high-grade serous ovarian carcinoma. Cell Rep. 2020;33:108276.","journal-title":"Cell Rep"},{"key":"1727_CR100","doi-asserted-by":"publisher","unstructured":"McDermott JE, Arshad OA, Petyuk VA, Fu Y, Gritsenko MA, Clauss TR, et al. Proteogenomic characterization of ovarian HGSC implicates mitotic kinases, replication stress in observed chromosomal instability. Cell Rep Med. 2020;1. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100004.","DOI":"10.1016\/j.xcrm.2020.100004"},{"key":"1727_CR101","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000539642","volume":"33","author":"Y Pan","year":"2024","unstructured":"Pan Y, Yang X, Chen M, Shi K, Lyu Y, Meeson AP, et al. Role of cancer side population stem cells in ovarian cancer angiogenesis. Med Princ Pract. 2024;33:403\u201313.","journal-title":"Med Princ Pract"},{"key":"1727_CR102","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024;9:170.","journal-title":"Signal Transduct Target Ther"},{"key":"1727_CR103","doi-asserted-by":"publisher","unstructured":"Clayton ZE, Tan RP, Miravet MM, Lennartsson K, Cooke JP, Bursill CA, et al. Induced pluripotent stem cell-derived endothelial cells promote angiogenesis and accelerate wound closure in a murine excisional wound healing model. Biosci Rep. 2018;38. https:\/\/doi.org\/10.1042\/BSR20180563.","DOI":"10.1042\/BSR20180563"},{"key":"1727_CR104","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10456-019-09669-x","volume":"22","author":"S Krishnapriya","year":"2019","unstructured":"Krishnapriya S, Sidhanth C, Manasa P, Sneha S, Bindhya S, Nagare RP, et al. Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. Angiogenesis. 2019;22:441\u201355.","journal-title":"Angiogenesis"},{"key":"1727_CR105","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00262-018-2251-8","volume":"67","author":"D Loukinov","year":"2018","unstructured":"Loukinov D. Targeting CTCFL\/BORIS for the immunotherapy of cancer. Cancer Immunol Immunother. 2018;67:1955\u201365.","journal-title":"Cancer Immunol Immunother"},{"key":"1727_CR106","doi-asserted-by":"publisher","first-page":"1121973","DOI":"10.3389\/fimmu.2023.1121973","volume":"14","author":"RA van Amerongen","year":"2023","unstructured":"van Amerongen RA, Tuit S, Wouters AK, van de Meent M, Siekman SL, Meeuwsen MH, et al. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. Front Immunol. 2023;14:1121973.","journal-title":"Front Immunol"},{"key":"1727_CR107","doi-asserted-by":"crossref","unstructured":"Oza A, Castonguay V, Tsoref D, Diaz-Padilla I, Karakasis K, Mackay H, et al. Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol. 2011;18. https:\/\/doi.org\/10.3390\/curroncol18060003?locatt=mode:legacy.","DOI":"10.3390\/curroncol18060003"},{"key":"1727_CR108","unstructured":"Winterhoff B, Kommoss S. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Datasets. Gene Expression Omnibus; 2019. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE140082."},{"key":"1727_CR109","unstructured":"The Cancer Genome Atlas Research Network. Gene expression RNAseq RSEM norm_counts and phenotype data. Datasets. UCSC Xena; 2016. https:\/\/xenabrowser.net\/datapages\/?cohort=TCGA%20Pan-Cancer%20(PANCAN)."},{"key":"1727_CR110","doi-asserted-by":"crossref","unstructured":"Zolotareva O. Transcriptome signature for the identification of bevacizumab responders in ovarian cancer. GitHub; 2026. https:\/\/github.com\/ozolotareva\/bevacizumab_ovca_signature.","DOI":"10.1186\/s13073-026-01727-6"},{"key":"1727_CR111","doi-asserted-by":"publisher","unstructured":"Zolotareva O. Transcriptome signature for the identification of bevacizumab responders in ovarian cancer. Zenodo; 2026. https:\/\/doi.org\/10.5281\/zenodo.21264218.","DOI":"10.5281\/zenodo.21264218"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01727-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01727-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01727-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:03:22Z","timestamp":1786359802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01727-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1727"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01727-6","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients gave written informed consent for biomaterial to be collected and for access to their clinical records. The study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the local ethics board (Ethik-Kommission der \u00c4rztekammer Hamburg: no. 190504 and PV6012-4312-BO-ff).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}